Good news for breast “connoisseurs” as the revolutionary  MemoryShape breast implants have been approved by the U.S. Food and  Drug Administration for breast augmentation in women aged 22 and older,  and also for breast reconstruction.
In a news release, the  manufacturer, Mentor Worldwide LLC, said the implants have been approved  outside of the United States for more than a decade. The product is  available in a range of sizes and is tear-drop shaped to mimic the  natural shape of a breast.
The product, which is very likely to be  available in Africa and possibly – Nigeria – has been clinically  studied among 955 augmentation and reconstruction patients participating  in an ongoing 10-year study.
However, after six years, the study has found a low rate of “adverse events” including rupture/
The  FDA said that it’s approval was based on six years of data from 95  women showing a reasonable assurance of safety and effectiveness for  this implant. Mentor’s MemoryShape Breast Implant showed similarrates of  complications and outcomes as previously approved breast implants.
These  complications included tightening of the area around the implant,  re-operation, implant removal, an uneven appearance(asymmetry), and  wrinkling. Fissures or cracks were observed in the gel of some  MemoryShape Breast Implants, a characteristic called gel fracture.
According  to Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and  Radiological Health, “It’s important to remember that breast implants  are not lifetime devices. Women should fully understand the risks  associated with breast implants before considering augmentation or  reconstruction surgery, and they should recognize that long-term  monitoring is essential.”
Breast implant surgery should not be performed on women with any
 active infection, untreated cancer or who are pregnant or nursing.
With this approval, there are now five FDA-approved silicone
 gel-filled breast implants available in the United States manufactured
 by three companies: Allergan, Mentor and Sientra.
Source: Vanguard 
 
No comments:
Post a Comment